Please login to the form below

Not currently logged in
Email:
Password:

Takeda wins UK approval for cancer drug

Takeda's bone cancer treatment Mepact has won the backing of the UK's National Institute for Health and Clinical Excellence

Takeda Pharmaceutical won the backing of the UK's National Institute for Health and Clinical Excellence (NICE) for its Mepact (mifamurtide) drug, for the treatment of high-grade resectable non-metastic osteosarcoma.

Mepact is approved for use with chemotherapy after surgery for bone cancers that have not spread. The approval is conditional on Takeda providing a price discount, which it has agreed to do, according to NICE.

The agency reversed a decision from 2010 in which it rejected the drug. The initial economic analysis may not have adequately captured the health-related quality of life from the drug, NICE said.

The terms of the discount have not been disclosed at Takeda's request.

Takeda acquired the rights to Mepact when it purchased IDM Pharma in May, 2009.

7th September 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Double Helix

Double Helix is an independent healthcare consultancy with headquarters in London and offices in the US and Singapore. Established in...

Latest intelligence

Blog_icon_anthill-celebrates-1500-digital-sales-presentations-300x200.png
Webinar: Become your customer’s chosen channel
Your customer now expects to access knowledge in any format and at any time that they desire. But how do you become the ever-present partner that they trust and value...
Understanding the chronic disease patient journey in emerging markets
...
Infographic: Keeping tracking on track
Our best practice approach to tracking studies....

Infographics